
About this episode
If you’ve listened to some of the dialogue in hearings on Capitol Hill about how to regulate AI, you’ve heard various folks suggest the need for a regulatory agency to govern, in particular, general purpose AI systems that can be deployed across a wide range of applications. One existing agency is often mentioned as a potential model: the Food and Drug Administration (FDA). But how would applying the FDA work in practice? Where does the model break down when it comes to AI and related technologies, which are different in many ways from the types of things the FDA looks at day to day? To answer these questions, Justin Hendrix spoke to Merlin Stein and Connor Dunlop, the authors of a new report published by the Ada Lovelace Institute titled Safe before sale: Learnings from the FDA’s model of life sciences oversight for foundation models.
Get every episode summarized
Each time The Tech Policy Press Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Tech Policy Press Podcast

AI, Gig Work, and the Future of Nursing
The Tech Policy Press Podcast

Unpacking the SECURE Data Act
The Tech Policy Press Podcast

Attorney General Raúl Torrez on What's Next in New Mexico's Case Against Meta
The Tech Policy Press Podcast

Why Palantir's ImmigrationOS Endangers Democracy and the Rule of Law
The Tech Policy Press Podcast